- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Pregabalin is a medicine that cures nerve pain by soothing the body's hyperactive nerves. It can also be used to treat epilepsy by avoiding and controlling seizures. Lyrica is the brand name for this medicine.
PREGABALIN (pre GAB a lin) is used to alleviate nerve pain. It might potentially be used to prevent and control seizures in persons suffering from epilepsy. It works by soothing the body's hyperactive nerves.This drug may also be used for other purposes; take it by mouth with water. Take it at the same time every day, as indicated on the prescription label. It can be taken with or without meals. Take it with meals if it bothers your stomach.
Continue taking it until the care team instructs to stop. There will be a customized MedGuide.Pregabalin is a medicine that cures nerve pain by soothing the body's hyperactive nerves. It can also be used to treat epilepsy by avoiding and controlling seizures. Lyrica is the brand name for this medicine.
PREGABALIN (pre GAB a lin) is used to alleviate nerve pain. It might potentially be used to prevent and control seizures in persons suffering from epilepsy. It functions by relaxing hyperactive nerves.Pregabalin is an anticonvulsant, analgesic, and anxiolytic medicine that is used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, opioid withdrawal, and generalized anxiety disorder (GAD).
Pregabalin has antiallodynic effects as well. It is used in epilepsy as a supplement treatment for partial seizures. It is a gabapentinoid medicine that works by blocking certain calcium channels. When administered prior to surgery, it decreases pain but increases drowsiness and causes visual abnormalities.
It is administered orally.Common adverse effects include headaches, dizziness, tiredness, disorientation, memory issues, poor coordination, dry mouth, visual problems, and weight gain.
Serious adverse effects include angioedema, drug abuse, and an increased risk of suicide. Addiction may arise when pregabalin is taken in high dosages over a long period of time, although the risk is low when taken at normal amounts. The safety of using it during pregnancy or nursing is unknown.
In the United States, pregabalin was licensed for medicinal usage. It was created as a replacement for the related gabapentin. It is accessible as a generic drug. In the United States, it was the 78th most widely prescribed medicine.When administered prior to surgery, it decreases pain but increases drowsiness and causes visual abnormalities. It is administered orally.
Common adverse effects include headaches, dizziness, tiredness, disorientation, memory issues, poor coordination, dry mouth, visual problems, and weight gain. Serious adverse effects include angioedema, drug abuse, and an increased risk of suicide. Addiction may arise when pregabalin is taken in high dosages over a long period of time, although the risk is low when taken at normal amounts. The safety of using it during pregnancy or nursing is unknown.
In the United States, pregabalin was licensed for medicinal usage. It was created as a replacement for the related gabapentin. It is accessible as a generic drug.In the United States, it was the 78th most widely prescribed medicine.Pregabalin can be used as an adjunct therapy to other therapies for drug-resistant focal epilepsy. It is less effective than certain other seizure drugs when used alone. It is uncertain how it compares to gabapentin in this use.
Pregabalin is recommended as a first-line therapy for pain associated with diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain by the European Federation of Neurological Societies. A small number of people profit significantly, whereas the majority benefit little. As a first-line treatment, it is accorded the same weight as gabapentin and tricyclic antidepressants, but the latter are less costly. Pregabalin relieves pain just as well as duloxetine and amitriptyline.
Pregabalin and amitriptyline or duloxetine combined therapy provides further pain relief for patients whose pain is not relieved by other medications.
Higher doses of pregabalin have been linked to better effectiveness in studies.The use of pregabalin in cancer-related neuropathic pain remains contentious, despite its widespread usage. It has been studied for the prevention of post-surgical chronic pain, although its usefulness for this purpose is debatable.
Pregabalin is not usually thought to be effective in the treatment of acute pain. There was no effect on overall pain levels in trials assessing the efficacy of pregabalin for the treatment of acute post-surgical pain, although participants did require less morphine and experienced fewer opioid-related adverse effects. Several potential methods for pain relief have been suggested.
Pregabalin is a safe and somewhat effective medication for generalized anxiety disorder. It is also useful in treating social anxiety disorder in both the short and long term.
The Global Pregabalin Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The North American market, particularly the USA, will be one of the prime markets for Pregabalin Market due to the nature of industrial automation in the region, high consumer spending compared to other regions, and the growth of various industries, mainly AI, along with constant technological advancements.
The GDP of the USA is one of the largest in the world, and it is home to various industries such as Pharmaceuticals, Aerospace, and Technology. The average consumer spending in the region was $72K in 2023, and this is set to increase over the forecast period. Industries are focused on industrial automation and increasing efficiency in the region.
This will be facilitated by the growth in IoT and AI across the board. Due to tensions in geopolitics, much manufacturing is set to shift towards the USA and Mexico, away from China. This shift will include industries such as semiconductors and automotive.
The European market, particularly Western Europe, is another prime market for Pregabalin Market due to the strong economic conditions in the region, bolstered by robust systems that support sustained growth. This includes research and development of new technologies, constant innovation, and developments across various industries that promote regional growth. Investments are being made to develop and improve existing infrastructure, enabling various industries to thrive.
In Western Europe, the margins forPregabalin Market are higher than in other parts of the world due to regional supply and demand dynamics. Average consumer spending in the region was lower than in the USA in 2023, but it is expected to increase over the forecast period.
Eastern Europe is anticipated to experience a higher growth rate compared to Western Europe, as significant shifts in manufacturing and development are taking place in countries like Poland and Hungary. However, the Russia-Ukraine war is currently disrupting growth in this region, with the lack of an immediate resolution negatively impacting growth and creating instability in neighboring areas.
Despite these challenges, technological hubs are emerging in Eastern Europe, driven by lower labor costs and a strong supply of technological capabilities compared to Western Europe.
There is a significant boom in manufacturing within Europe, especially in the semiconductor industry, which is expected to influence other industries. Major improvements in the development of sectors such as renewable energy, industrial automation, automotive manufacturing, battery manufacturing and recycling, and AI are poised to promote the growth ofPregabalin Market in the region.
Asia will continue to be the global manufacturing hub for Pregabalin Market over the forecast period with China dominating the manufacturing. However, there will be a shift in manufacturing towards other Asian countries such as India and Vietnam.
The technological developments will come from China, Japan, South Korea, and India for the region. There is a trend to improve the efficiency as well as the quality of goods and services to keep up with the standards that are present internationally as well as win the fight in terms of pricing in this region.
The demand in this region will also be driven by infrastructural developments that will take place over the forecast period to improve the output for various industries in different countries. There will be higher growth in the Middle East as investments fall into place to improve their standing in various industries away from petroleum.
Plans such as Saudi Arabia Vision 2030, Qatar Vision 2030, and Abu Dhabi 2030 will cause developments across multiple industries in the region. There is a focus on improving the manufacturing sector as well as the knowledge-based services to cater to the needs of the region and the rest of the world. Due to the shifting nature of fossil fuels, the region will be ready with multiple other revenue sources by the time comes, though fossil fuels are not going away any time soon.
Africa is expected to see the largest growth inPregabalin Marketover the forecast period, as the region prepares to advance across multiple fronts. This growth aligns with the surge of investments targeting key sectors such as agriculture, mining, financial services, manufacturing, logistics, automotive, and healthcare.
These investments are poised to stimulate overall regional growth, creating ripple effects across other industries as consumer spending increases, access to products improves, and product offerings expand.
This development is supported by both established companies and startups in the region, with assistance from various charitable organizations. Additionally, the presence of a young workforce will address various existing regional challenges.
There has been an improvement in political stability, which has attracted and will continue to attract more foreign investments. Initiatives like the African Continental Free Trade Area (AfCFTA) are set to facilitate the easier movement of goods and services within the region, further enhancing the economic landscape.
Latin America and the Oceania region will showcase growth over the forecast period inPregabalin Market). In Latin America, the focus in the forecast period will be to improve their manufacturing capabilities which is supported by foreign investments in the region.
This will be across industries mainly automotive and medical devices. There will also be an increase in mining activities over the forecast period in this region. The area is ripe for industrial automation to enable improvements in manufacturing across different industries and efficiency improvements. This will lead to growth of other industries in the region.
| Margin Comparison (Highest to lowest) | Region | Remarks |
| 1 | Europe | The supply chain demands and the purchasing power in the region enable suppliers to extradite a larger margin from this region than other regions. This is for both locally manufactured as well as imported goods and services in the region. |
| 2 | North America | Due to the high spending power in this region, the margins are higher compared to the rest of the world, but they are lower than Europe as there is higher competition in this region. All the suppliers of goods and services target USA as a main market thereby decreasing their margins compared to Europe |
| 3 | Asia | Lower purchasing power, coupled with higher accessibility of services in this regions doesnât enable suppliers to charge a high margin making it lower than Europe and North America. The quality of goods and services are also affected due to this aspect in the region |
| 4 | Africa and ROW | The margins are the lowest in this region, except for Australia and New Zealand as the countries in this region donât have much spending power and a large portion of the products and services from this area is exported to other parts of the world |
Pfizer Inc. (NYSE: PFE) announced today that the FDA has approved LYRICA CR (pregabalin) extended-release tablets CV as once-daily therapy for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and postherpetic neuralgia (PHN).
LYRICA CR was not approved for the treatment of fibromyalgia.LYRICA CR was created to provide patients with an effective therapy alternative with the ease of once-daily administration. It is a crucial alternative for people and health care professionals who are dealing with these frequently excruciating pain disorders.
In a randomized placebo-controlled clinical study, the effectiveness and safety of LYRICA CR in PHN were established in a total of Patients with PHN who began single-blind therapy with LYRICA CR. Because both pDPN and PHN are peripheral neuropathic pain disorders; the PHN data supported both the pDPN and PHN diagnoses. A six-week single-blind, dosage optimization phase was followed by a 13-week double-blind phase in the randomized study.
In the PHN trial, % of patients in the LYRICA CR group saw at least % relief in pain intensity, compared to 5% in the placebo group.Dizziness, somnolence, headache, tiredness, peripheral edema, nausea, blurred vision, dry mouth, and weight gain were the most prevalent side effects observed with LYRICA CR.
Pregabalin is one of several first-line medicines recommended by the World Federation of Biological Psychiatry for the treatment of generalized anxiety disorder, although other agents, such as SSRIs, are recommended as first-line treatment for obsessive-compulsive disorder and post-traumatic stress disorder.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.